Clinical Trials As an NCI-designated Comprehensive Cancer Center and a lead site for the National Clinical Trials Net- work, we provide national leadership in developing clinical trials, which offer more options for patients. With more than 300 open therapeutic trials available, we enroll nearly 1,000 patients each year. For a full listing, visit • Oropharyngeal Tumor Induction Chemotherapy and Response-stratified Locoregional Therapy Trial in Order to Minimize Long-term Adverse Events (OPTIMA II), IRB 17-0104 • A Randomized, Double-Blind Phase II Study of Adjuvant Pembrolizumab Versus Placebo in Head and Neck Cancers at High Risk for Recur- rence—the PATHWay Study, IRB 15-1632 • Study of Nivolumab in Combination With Ipilimumab Compared to the Standard of Care (Extreme Study Regimen) as First Line Treat- ment in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck (CheckMate 651), IRB 16-0680 • The Women Choosing Surgical Prevention (WISP) Trial for Hereditary Breast and Ovarian Cancer, IRB 16-0606 The 7th Annual Clinical Cancer Genetics and Genomics Conference: Frontiers in Precision Medicine for Inherited Cancers: From Risk Assessment to Targeted Therapies APRIL 20–21, 2018 Gwen Hotel, 521 North Rush St., Chicago, IL 60611 To register, visit Upcoming Events 20–21 APRIL Research CANCER.UCHICAGO.EDU 9